PRKG2

Across TCGA pan-cancer cohorts, PRKG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PRKG2 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PRKG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKG2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, PDAC, and LUAD are the cancer types where PRKG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.947	0.607	.030	11	view →
PDAC	DFS	Median	All	0.305	0.834	.049	4	view →
LUAD	OS	Tertile	III,IV	0.531	0.879	.042	2	view →
LSCC	DFS	Tertile	All	0.569	0.793	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PRKG2–GBM (DFS)

Open the GBM breakdown →